<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870283</url>
  </required_header>
  <id_info>
    <org_study_id>09-013</org_study_id>
    <nct_id>NCT02870283</nct_id>
  </id_info>
  <brief_title>Cost- Effectiveness and Quality of Life Assessment in Mood Disorder</brief_title>
  <official_title>Assessment of Cost- Effectiveness Interventions and the Quality of Life in Patients With Mood Disorders Through Resources Available in Brazilian Public Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Rio Grande do Sul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of Rio Grande do Sul</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of three systematic interventions for Bipolar Disorder (BD)
      mixed episodes using medications available in the Brazilian Public Healthcare System (SUS),
      and assessment of the quality of life of these patients.

      A randomized pragmatic trial was conducted. An algorithm was developed for the treatment of
      episodes of bipolar mixed episodes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design was that of a pragmatic randomized clinical trial to evaluate the
      effectiveness of treatments for mood disorders in a public healthcare context in the city of
      Porto Alegre, in southern Brazil. The algorithm was originally developed for the treatment of
      mixed episodes by a Delphi panel of experts from psychiatric associations in Brazil. All
      subjects provided an informed consent form, in writing, in order to participate in the study
      protocol, which was approved by the institutional ethics committee.

      Procedures and measurements of the study

      The subjects under evaluation were selected and they followed the stages defined by the
      treatment protocol:

        1. Sample selection by being referred from the primary healthcare clinics in the
           municipality;

        2. Informative talk about mood disorders and the research, with the informed consent forms
           being provided to the subjects;

        3. Screening for BD mixed episodes with the use of the Patient Health Questionnaire
           (PHQ-9), and Hypomanic Symptoms Checklist Brazilian Version (HCL -32-BV);

        4. Diagnostic evaluation through the Mini International Neuropsychiatric Interview (MINI)
           and clinical interview for individuals with positive results in the screening
           instruments;

        5. Baseline and demographic assessments using standardized semi-structured interviews in
           the first and second visits;

        6. In each clinic visit, the severity of the symptoms were evealuated using the Clinical
           Global Impression Scale (CGI), Hamilton Rating Scale for Depression (HRSD), and Young
           Manic Rating Scale (YMRS);

        7. Biweekly follow-up, changed to monthly after stabilization - with a maximum follow-up
           period of 52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>8 weeks</time_frame>
    <description>The main outcomes were response to treatment and remission of symptoms. Response to treatment was defined as a 50% reduction from baseline in HRSD and YMRS scales.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission</measure>
    <time_frame>8 months</time_frame>
    <description>The remission outcome was established as obtaining three consecutive scores of values considered asymptomatic (HRSD &lt;7 points, and YMRS &lt;6 points). The subjects that were asymptomatic for at least 6-8 month were considered to be in remission, according to the criteria for partial and complete remission in the DSM-IV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>QOL scores as measured by World Heath Organization Quality of Life - WHOQOL -BREF instrument.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Lithium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).
Group (A) Started Lithium (900mg-1500mg)
Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
First step: Monotherapy with Lithium (900-1500mg) Non responsive patients: 2nd step.
Second step: Randomization for lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) OR lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).
Non responsive patients: 3rd step.
Third step: Crossover lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) X lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).
Non responsive patients: 4th step.
Fourth step: Association with risperidone (1-6mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acid Valproic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).
Group (B) Started Valproic Acid (1000mg-1500mg).
Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
First step: Monotherapy with Valproic Acid (1000mg-1500mg) Non responsive patients: 2nd step.
Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.
Third step: Crossover: lithium (900mg-1500mg) + carbamazepine (600mg-1200mg). Non responsive patients: 4th step.
Fourth step: Association with risperidone (1-6mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbamazepine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).
Group (C) Started Carbamazepine (600mg-1200mg).
Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
First step: Monotherapy with Carbamazepine (600mg-1200mg). Non responsive patients: 2nd step.
Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.
Third step: Crossover: lithium (900mg-1500mg) + valproic acid (1000mg-1500mg). Non responsive patients: 4th step.
Fourth step: Association with risperidone (1-6mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <arm_group_label>Lithium</arm_group_label>
    <other_name>carbolitium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <arm_group_label>Acid Valproic</arm_group_label>
    <other_name>depakene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine</intervention_name>
    <arm_group_label>Carbamazepine</arm_group_label>
    <other_name>tegretol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ages between 18 and 65;

          2. BD current acute mixed episode;

          3. total capacity to understand and respond to self-applied instruments;

          4. the presence of symptoms in the last 30 days;

          5. abstinence for at least 30 days for drug addicts.

        Exclusion Criteria:

          1. presence of Organic Brain Syndrome (OBS);

          2. pregnancy or lactation;

          3. criteria for psychiatric hospitalization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo Fleck, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Rio Grande do Sul</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Rio Grande do Sul</investigator_affiliation>
    <investigator_full_name>Ana Fl√°via Barros da Silva Lima</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cost effectiveness</keyword>
  <keyword>Bipolar disorder</keyword>
  <keyword>Mixed episodes</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

